EBV-VCA IgG ELISA kit

CAT#: EA100941

EBV-VCA IgG ELISA kit

Specifications

Product Data

• Format: 8x12 divisible strips
• Assay Type: Solid Phase Sandwich ELISA
• Assay Length: 3 hours
• Signal: Colorimetric
• Sample Type: Serum
• Sample Volume: 10 µl
• Specificity: This kit is used for quantitative detection human Epstein-Barr Virus-Viral Capsid Antigen (EBV-VCA) IgG
• Reactivities: Human
• Cross Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Interference: No significant interference observed with available related molecules.
• Components:
  • 1. Microwells coated with EBV-VCA antigen: 12x8x1
  • 2. Sample Diluent: 1 bottle (ready to use): 22 ml
  • 3. Calibrator: 1 Vial (ready to use): 1ml
  • 4. Positive Control: 1 vial (ready to use): 1ml
  • 5. Negative Control: 1 vial (ready to use): 1ml
  • 6. Enzyme conjugate: 1 bottle (ready to use): 12ml
  • 7. TMB Substrate: 1 bottle (ready to use): 12ml
  • 8. Stop Solution: 1 bottle (ready to use): 12ml
  • 9. Wash concentrate 20X: 1 bottle: 25ml
• Background: Epstein-Barr virus (EBV) is a herpes virus known to cause infectious mononucleosis (IM). EBV infection may demonstrate a wide spectrum of clinical symptoms. The majorities of primary EBV infections are transmitted via saliva, occur during childhood, and are sub-clinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years; 80% by adulthood. Transfusion-associated EBV infections have also been reported. Epstein-Barr virus has also been associated in the pathogenisis of two human cancers, Burkitt's lymphoma and nasopharyngeal carcinoma. Burkitt's lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China.